Pfizer jabs delivers less antibodies against Delta variation of Covid: Lancet study Kumar Jeetendra | June 4, 2021 People fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant first identified in India compared to the original strain, according to research published in The Lancet journal. The study also shows that levels of these antibodies that are able to recognise …
Administrative gesture for conducting clinical trials of Colchicine on COVID-19 patients: CSIR Kumar Jeetendra | June 12, 2021 The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday. Ram Vishwakarma, the advisor to the CSIR Director General, said Colchicine in combination with standard care will be an important therapeutic …
Pfizer, Moderna vaccines cut COVID-19 danger by 91%: Study Kumar Jeetendra | July 8, 2021 People who receive COVID-19 vaccines by Pfizer and Moderna are up to 91 per cent less likely to develop the disease, according to a US study which also suggests that the preventives reduce the severity of symptoms and duration in those who still get an infection. The research, published in the New England Journal of …
Consolidating AstraZeneca and mRNA COVID-19 vaccine is effective – Danish study Kumar Jeetendra | August 2, 2021 Combining AstraZeneca’s COVID-19 vaccine with a second dose from either Pfizer-BioNTech or Moderna’s jab provides “good protection”, Denmark’s State Serum Institute said on Monday. A growing number of countries are looking at switching to different COVID-19 vaccines for second doses, a measure particularly necessary in Denmark after health authorities discontinued inoculations with AstraZeneca’s vaccine in …
Provided more than 1 billion COVID-19 vaccine dose up until now: BioNTech Kumar Jeetendra | August 9, 2021 BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca, the German biotech group said on Monday. The supply tally, up from more than 700 million doses announced by the biotech firm in June, compares with AstraZeneca saying …
